Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in INVA — Innoviva, Inc.

CIK 1423053 MIAMI, FL
Back to INVA Full portfolio

Position in INVA

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$4,102,594
+$538,098 QoQ
Shares Held
176,077
-1.3% QoQ
Ownership
0.239%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in INVA Over Time

Shares Held

Position Value (USD)

Derivatives in INVA

reported options exposure · as of Mar 31, 2026
CallValue
$428,720
CallShares
18,400
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. INVA ranks #143 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in INVA

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $428,720 18,400
2026-03-31 $4,102,594 176,077
2025-12-31 $627,686 31,400
2025-12-31 $3,564,496 178,314
2025-09-30 $18,013,060 987,017
2025-09-30 $1,790,325 98,100
2025-06-30 $28,894,301 1,438,243
2025-06-30 $1,876,406 93,400
2025-03-31 $41,699 2,300
2025-03-31 $43,512 2,400
2025-03-31 $13,121,678 723,755
2024-12-31 $13,880 800
2024-12-31 $5,484,611 316,116
2024-12-31 $199,525 11,500
2024-09-30 $5,793 300
2024-09-30 $243,306 12,600
2024-09-30 $9,451,375 489,455
2024-06-30 $328,000 20,000
2024-06-30 $1,680,179 102,450
2024-06-30 $88,560 5,400
2024-03-31 $1,161,089 76,187
2024-03-31 $109,728 7,200
2024-03-31 $214,884 14,100
2023-12-31 $54,536 3,400
2023-12-31 $4,520,136 281,804
2023-12-31 $187,668 11,700
2023-09-30 $2,358,308 181,548
2023-09-30 $209,139 16,100
2023-09-30 $237,717 18,300
2023-06-30 $249,508 19,600
2023-06-30 $161,671 12,700
2023-06-30 $9,323,540 732,407
2023-03-31 $9,547,053 848,627
2023-03-31 $67,500 6,000
2023-03-31 $13,500 1,200
2022-12-31 $66,250 5,000
2022-12-31 $80,825 6,100
2022-12-31 $13,058,391 985,539
2022-09-30 $874,233 75,300
2022-09-30 $9,728,529 837,944
2022-06-30 $1,298,880 88,000
2022-06-30 $8,861,047 600,342
2022-03-31 $8,803,823 454,978
2022-03-31 $284,445 14,700
2022-03-31 $1,615,725 83,500
2021-12-31 $479,550 27,800
2021-12-31 $592,399 34,342
2021-09-30 $720,201 43,100
2021-09-30 $274,044 16,400
2021-09-30 $6,531,588 390,879

Report a Problem

Category
Description
Email (optional, for follow-up)